Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1981 2
1982 12
1983 3
1984 2
1985 4
1986 9
1987 13
1988 7
1989 18
1990 23
1991 18
1992 15
1993 11
1994 18
1995 10
1996 16
1997 18
1998 14
1999 10
2000 10
2001 14
2002 7
2003 17
2004 4
2005 8
2006 9
2007 9
2008 6
2009 11
2010 8
2011 5
2012 14
2013 8
2014 8
2015 7
2016 5
2017 6
2018 3
2019 2
2020 6
2021 2
2022 3
2023 3
2024 3
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

381 results

Results by year

Filters applied: . Clear all
Page 1
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.
Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM, Kupfer DJ, Rosenbaum JF, Alpert J, Stewart JW, McGrath PJ, Biggs MM, Shores-Wilson K, Lebowitz BD, Ritz L, Niederehe G; STAR*D Investigators Group. Rush AJ, et al. Control Clin Trials. 2004 Feb;25(1):119-42. doi: 10.1016/s0197-2456(03)00112-0. Control Clin Trials. 2004. PMID: 15061154 Clinical Trial.
After receiving citalopram (level 1), participants without sufficient symptomatic benefit are eligible for randomization to level 2 treatments, which entail four switch options (sertraline, bupropion, venlafaxine, cognitive therapy) and three citalopram augment options (bupropion …
After receiving citalopram (level 1), participants without sufficient symptomatic benefit are eligible for randomization to level 2 treatmen …
Buspirone for early satiety and symptoms of gastroparesis: A multi-centre, randomised, placebo-controlled, double-masked trial (BESST).
Parkman HP, Yates KP, Sarosiek I, Bulat RS, Abell TL, Koch KL, Kuo B, Grover M, Farrugia G, Silver P, Abdullah A, Maurer AH, Malik Z, Miriel LA, Tonascia J, Hamilton F, Pasricha PJ, McCallum RW; NIDDK Gastroparesis Clinical Research Consortium. Parkman HP, et al. Aliment Pharmacol Ther. 2023 Jun;57(11):1272-1289. doi: 10.1111/apt.17479. Epub 2023 Apr 13. Aliment Pharmacol Ther. 2023. PMID: 37052334 Free PMC article. Clinical Trial.
BACKGROUND: Patients with gastroparesis and related disorders have symptoms including early satiety, postprandial fullness and bloating. Buspirone, a 5-HT(1) receptor agonist, may improve fundic accommodation. AIM: To determine if buspirone treatment improves early …
BACKGROUND: Patients with gastroparesis and related disorders have symptoms including early satiety, postprandial fullness and bloating. …
Buspirone: anxiolytic?
Pecknold JC, Familamiri P, Chang H, Wilson R, Alarcia J, McClure DJ. Pecknold JC, et al. Prog Neuropsychopharmacol Biol Psychiatry. 1985;9(5-6):639-42. doi: 10.1016/0278-5846(85)90032-6. Prog Neuropsychopharmacol Biol Psychiatry. 1985. PMID: 2868495 Clinical Trial.
Dizziness was the most prominent adverse effect in the buspirone group, whereas the diazepam group had more adverse effects including sedation, fatigue, dizziness and impaired concentration. Withdrawal symptoms were more evident in the diazepam group than the buspirone …
Dizziness was the most prominent adverse effect in the buspirone group, whereas the diazepam group had more adverse effects including …
A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability.
Schneider RB, Auinger P, Tarolli CG, Iourinets J, Gil-Díaz MC, Richard IH. Schneider RB, et al. Parkinsonism Relat Disord. 2020 Dec;81:69-74. doi: 10.1016/j.parkreldis.2020.10.020. Epub 2020 Oct 13. Parkinsonism Relat Disord. 2020. PMID: 33070009 Free PMC article. Clinical Trial.
In the buspirone group, 7 (41%) failed to complete the study on drug, 5 due to intolerability. The median buspirone dosage was 7.5 mg twice daily. No serious adverse events occurred. A total of 9 (53%) buspirone participants experienced adverse events consist …
In the buspirone group, 7 (41%) failed to complete the study on drug, 5 due to intolerability. The median buspirone dosage was …
Assessing the efficacy and safety of combined buspirone and venlafaxine treatment in late-life depression accompanied by cognitive impairment: A randomized controlled trial.
Hu S, Chen K, Xu Q, Wang F, Na W. Hu S, et al. Gen Hosp Psychiatry. 2024 Nov-Dec;91:1-10. doi: 10.1016/j.genhosppsych.2024.09.001. Epub 2024 Sep 3. Gen Hosp Psychiatry. 2024. PMID: 39243483 Clinical Trial.
While antidepressants like venlafaxine and anxiolytics such as buspirone are effective for treating depression, their effects on cognitive function remain less well-understood. ...OBJECTIVE: This study aimed to evaluate the clinical efficacy and safety of combined buspi …
While antidepressants like venlafaxine and anxiolytics such as buspirone are effective for treating depression, their effects on cogn …
A clinical trial of buspirone and diazepam in the treatment of generalized anxiety disorder.
Ross CA, Matas M. Ross CA, et al. Can J Psychiatry. 1987 Jun;32(5):351-5. doi: 10.1177/070674378703200505. Can J Psychiatry. 1987. PMID: 3308052 Clinical Trial.
We conducted a 4 week double-blind, randomized trial of buspirone versus diazepam and placebo in thirty adult outpatients with generalized anxiety disorder. Maximum doses were 40 mg of diazepam or buspirone or eight placebo tablets a day. There were no significant d …
We conducted a 4 week double-blind, randomized trial of buspirone versus diazepam and placebo in thirty adult outpatients with genera …
Comparison of the Efficacy of Buspirone and Placebo in Childhood Functional Abdominal Pain: A Randomized Clinical Trial.
Badihian N, Yaghini O, Badihian S, Shahsanai A, Saneian H. Badihian N, et al. Am J Gastroenterol. 2020 May;115(5):756-765. doi: 10.14309/ajg.0000000000000589. Am J Gastroenterol. 2020. PMID: 32221160 Clinical Trial.
RESULTS: Ninety-five patients completed the 4-week therapy (48 and 47 in buspirone and placebo groups, respectively). Both buspirone and placebo reduced pain after 4 weeks of treatment, and these effects were persistent 8 weeks after medication discontinuation (P &l …
RESULTS: Ninety-five patients completed the 4-week therapy (48 and 47 in buspirone and placebo groups, respectively). Both buspiro …
A double-blind, randomized, placebo-controlled, pilot clinical trial examining buspirone as an adjunctive medication during buprenorphine-assisted supervised opioid withdrawal.
Bergeria CL, Tan H, Antoine D, Weerts EM, Huhn AS, Hobelmann JG, Dunn KE. Bergeria CL, et al. Exp Clin Psychopharmacol. 2023 Feb;31(1):194-203. doi: 10.1037/pha0000550. Epub 2022 Mar 10. Exp Clin Psychopharmacol. 2023. PMID: 35266779 Free PMC article. Clinical Trial.
Greater decreases in withdrawal were observed during Week 2 of stable buspirone relative to Week 1 of stable buspirone. Participants also reported significant increases in sleep duration and significant decreases in latency to sleep onset. This study provides furthe …
Greater decreases in withdrawal were observed during Week 2 of stable buspirone relative to Week 1 of stable buspirone. Partic …
A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism.
Ghanizadeh A, Ayoobzadehshirazi A. Ghanizadeh A, et al. Pediatr Neurol. 2015 Jan;52(1):77-81. doi: 10.1016/j.pediatrneurol.2014.09.017. Epub 2014 Oct 5. Pediatr Neurol. 2015. PMID: 25451017 Clinical Trial.
RESULTS: Eighteen patients in the placebo group and 16 patients in the buspirone group completed this trial. The mean dose of buspirone was 6.7 (SD 2.7) mg/day. ...The most common adverse effects in the buspirone group were increased appetite, drowsiness, and …
RESULTS: Eighteen patients in the placebo group and 16 patients in the buspirone group completed this trial. The mean dose of busp …
Benefit of buspirone on chemoreflex and central apnoeas in heart failure: a randomized controlled crossover trial.
Giannoni A, Borrelli C, Mirizzi G, Richerson GB, Emdin M, Passino C. Giannoni A, et al. Eur J Heart Fail. 2021 Feb;23(2):312-320. doi: 10.1002/ejhf.1854. Epub 2020 May 22. Eur J Heart Fail. 2021. PMID: 32441857 Free article. Clinical Trial.
In the intention-to-treat analysis, more patients treated with buspirone (8/16, 50%) had a CO(2) chemosensitivity reduction >0.5 L/min/mmHg from baseline than those treated with placebo (1/16, 6.7%) (difference between groups 43%, 95% confidence interval 14-73%, P = 0.0 …
In the intention-to-treat analysis, more patients treated with buspirone (8/16, 50%) had a CO(2) chemosensitivity reduction >0.5 L …
381 results